Vicinitas Therapeutics Launches With $65 Million In Series A Financing To Advance Precision Medicines To Stabilize Key Proteins To Treat Disease
Amount Raised
$65 Million
Round Type
Series A
San FranciscoBiotechnologyHealth CareTherapeuticsDescription
Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing. The financing was co-led by a16z and Deerfield Management, with participation from Droia Ventures, GV, The Mark Foundation for Cancer Research and the Berkeley Catalyst Fund. Vicinitas Therapeutics is a spin-out company that resulted from the Deubiquitinase Targeting Chimera (DUBTAC) platform, which was developed through an academic-industry research collaboration between the Novartis Institutes for BioMedical Research and researchers at the University of California, Berkeley.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Vicinitas Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Photys Therapeutics raised $75M (Series A) on September 8, 2022.
- Autobahn Therapeutics raised an undisclosed amount (Funding Round) on September 8, 2022.
- Inherent Biosciences raised an undisclosed amount (Series A) on September 7, 2022.
- SpringWorks raised $225M (Post-IPO Equity) on September 7, 2022.
- Arsenal Biosciences raised $220M (Series B) on September 6, 2022.
- Lento Bio raised $680K (Seed) on September 6, 2022.
Who to call at Vicinitas Therapeutics, and when
A new round usually means Vicinitas Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Vicinitas Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vicinitas Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vicinitas Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vicinitas Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansVicinitas Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.